Business Context and Reporting Period
Syndax Pharmaceuticals Inc. (SNDX) filed a Form 8-K on December 8, 2020, reporting the entry into a material definitive agreement. The company is an emerging growth company incorporated in Delaware with principal executive offices in Waltham, Massachusetts.
Key Financial Metrics and Transaction Details
This filing details a public offering of common stock rather than periodic financial results. Key transaction metrics include:
- Shares Issued: 5,434,783 shares of common stock.
- Offering Price: $23.00 per share.
- Over-Allotment Option: Underwriters granted an option to purchase up to an additional 815,217 shares.
- Expected Net Proceeds: Approximately $117.2 million (or approximately $134.8 million if the over-allotment option is exercised in full), after deducting underwriting discounts, commissions, and estimated offering expenses.
- Underwriters: Goldman Sachs & Co. LLC, Citigroup Global Markets Inc., and Cowen and Company, LLC.
The filing text does not provide current revenue, profit, cash flow, margins, or debt figures.
Material Changes and Agreements
The primary material change is the execution of the Underwriting Agreement to raise capital. The offering is expected to close on or about December 11, 2020, subject to customary closing conditions. The transaction is being made pursuant to a shelf registration statement on Form S-3 declared effective on September 10, 2019.
Management Commentary, Risks, and Lock-Up Provisions
As part of the Underwriting Agreement, the Company's directors and executive officers have agreed not to sell or transfer any shares of Common Stock for 60 days following December 8, 2020, subject to certain exceptions. Similarly, the Company has agreed not to sell or transfer any shares of its common stock for 60 days without the written consent of Goldman Sachs & Co. LLC. The agreement contains customary representations, warranties, covenants, and indemnification obligations.
Investor Verification Checklist
- Verify the final closing date of the offering (expected December 11, 2020).
- Confirm whether the underwriters exercised the option to purchase the additional 815,217 shares.
- Review the final prospectus supplement for exact net proceeds after all expenses.
- Monitor the company's cash position post-closing to assess runway for clinical development.
- Check for any subsequent filings regarding the 60-day lock-up expiration.